Abstract
Patients with superficial vein thrombosis (SVT) are commonly treated with low-molecular weight heparin or fondaparinux in prophylactic, intermediate or therapeutic dosages for treatment periods of 10–45 days. This practice is also reflected by the current guideline recommendations. However, given the broad range of thromboembolic complication rates in SVT (between 0 and 30 % have been reported) it seems reasonable to suspect that risk stratification is needed to differentiate patients at low risk who may not benefit from anticoagulation from those at high risk who may need higher dosages or a longer duration of anticoagulation. Furthermore, prolonged treatment with injectable anticoagulants has been shown to result in poor patient adherence. Direct oral anticoagulants have recently been approved for venous thromboembolism therapy and these new drugs may offer advantages also for SVT patients. The prospective, randomized, open-label, blinded adjudication trial superficial phlebitis treated for 45 days with rivaroxaban versus fondaparinux (SURPRISE) will evaluate the efficacy and safety of 10 mg rivaroxaban OD compared to fondaparinux 2.5 mg OD for SVT treatment in a subset of high-risk SVT patients over a treatment period of 45 days. The purpose of the study is to demonstrate non-inferiority of rivaroxaban compared to fondaparinux in preventing the combined efficacy endpoint of thrombus progression, SVT recurrence, DVT, PE and death. The results of the SURPRISE trial will provide evidence for the concept of risk stratification in SVT and for the value of rivaroxaban 10 mg in SVT treatment (clinicaltrials.gov NCT01499953).
Similar content being viewed by others
References
Coon WW, Willis PW 3rd, Keller JB (1973) Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 48(4):839–846
Frappe P, Buchmuller-Cordier A, Bertoletti L, Bonithon-Kopp C, Couzan S, Lafond P, Leizorovicz A, Merah A, Presles E, Preynat P, Tardy B, Decousus H (2014) Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. J Thromb Haemost 12(6):831–838
Decousus H, Quere I, Presles E, Becker F, Barrellier MT, Chanut M, Gillet JL, Guenneguez H, Leandri C, Mismetti P, Pichot O, Leizorovicz A (2010) Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 152(4):218–224
Karathanos C, Exarchou M, Tsezou A, Kyriakou D, Wittens C, Giannoukas A (2013) Factors associated with the development of superficial vein thrombosis in patients with varicose veins. Thromb Res 132(1):47–50
Decousus H, Bertoletti L, Frappe P (2015) Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat? J Thromb Haemost 13(Suppl 1):S230–S237
Galanaud JP, Genty C, Sevestre MA, Brisot D, Lausecker M, Gillet JL, Rolland C, Righini M, Leftheriotis G, Bosson JL, Quere I (2011) Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost 105(1):31–39
Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A (2010) Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363(13):1222–1232
STENOX study group (2003) A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 163(14):1657–1663
Prandoni P, Tormene D, Pesavento R (2005) High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 3(6):1152–1157
Cosmi B, Filippini M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G (2012) A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 10(6):1026–1035
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S
Blondon M, Righini M, Bounameaux H, Veenstra DL (2011) Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis. Chest 141(2):321–329
Wilke T, Moock J, Muller S, Pfannkuche M, Kurth A (2010) Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res 468(9):2437–2453
Quenet S, Laporte S, Decousus H, Leizorovicz A, Epinat M, Mismetti P (2003) Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. J Vasc Surg 38(5):944–949
Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694
Einstein-Investigators Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:10.1056/NEJMoa1007903
Einstein-PE-Investigators Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi:10.1056/NEJMoa1113572
Authors’ contribution
JBW wrote the first draft of the trial protocol and is the lead investigator of SURPRISE. SW wrote the first draft of this manuscript. RB, HG, ER, SMSS and JBW represent the Steering Committee of SURPRISE and contributed to the design and oversight of the study. All authors contributed to the preparation of this manuscript and approved the final version.
Funding
This investigator-initiated trial is sponsored by funding of the Bayer Vital GmbH. The company also provides the investigational product.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
SW has received research support and honoraria for lectures and advisory boards from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, LeoPharma and Pfizer. RB has received research support and honoraria for lectures and advisory boards from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Boehringer and Daiichi Sankyo, and ASPEN. HG has received honoraria for lectures and advisory boards from Aspen, Bayer, Boehringer-Ingelheim and LeoPharma. ER has received honoraria for lectures and advisory boards from Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, LeoPharma and Pfizer. SMS has received honoraria for lectures and advisory boards from Bayer, Pfizer, Boehringer-Ingelheim, Daiichi-Sankyo and LeoPharma. JBW has received research support and honoraria for lectures and advisory boards from Bayer, Pfizer, Boehringer-Ingelheim, Daiichi-Sankyo and LeoPharma.
Rights and permissions
About this article
Cite this article
Werth, S., Bauersachs, R., Gerlach, H. et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombolysis 42, 197–204 (2016). https://doi.org/10.1007/s11239-016-1354-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-016-1354-3